A phase 1 clinical trial in China comparing the tocilizumab biosimilar candidate LZM008 to the reference product (Actemra) found pharmacokinetic (PK) parameters within the bioequivalence margins and similar immunogenicity and safety in healthy participants.
A phase 1 clinical trial in China comparing the tocilizumab biosimilar candidate LZM008 (Livzon Mabpharm) to the reference product (Actemra) found pharmacokinetic (PK) parameters within the bioequivalence margins and similar immunogenicity and safety in healthy participants.
Tocilizumab is a recombinant humanized monoclonal antibody to the interleukin-6 receptor. The originator is approved to treat rheumatoid arthritis (RA) in China, the United States, and Europe. Preclinical studies demonstrated “high similarities” between LZM008 and the originator, the authors said, adding that, at the time of writing, there was no biosimilar tocilizumab product available in China. China’s National Medical Products Administration approved Bio-Thera Solutions’ tocilizumab biosimilar BAT1806 for RA in January 2023.
The randomized, double-blind study evaluated PK, safety, and immunogenicity parameters for 28 days following a single intravenous dose of the biosimilar (n = 49) or reference product (n = 47). The investigators said the 2 groups were “well balanced and comparable” regarding demographics and baseline characteristics.
PK Parameters Met Equivalence Criteria
Similar PK properties were observed, with 90% CI of ratios for all pharmacokinetic parameters measured within the equivalence range of 80% and 125%. CIs for the primary endpoints maximum serum concentration (Cmax) and area under the concentration-time curve (AUC) from time 0 to the last detectable drug concentration (AUC0-t) were 105% to 119% and 103% to 115%, and 105% to 119% for the secondary endpoint AUC from time 0 to infinity (AUC0-∞). “Overall, PK profiles were similar in the two groups and can meet the bioequivalence criterion.”the authors concluded.
Safety and Immunogenicity
The incidence of treatment emergent adverse events (TEAEs) was similar in the LZM008 and reference tocilizumab groups, with 98% and 100% of patients experiencing TEAEs, respectively. The most common were decreases in blood fibrinogen and neutrophil counts. In the biosimilar group 8% of subjects had TEAEs of grade 3 or worse compared to 13% in the reference product group. No serious adverse events or TEAEs leading to discontinuation of treatment or death were observed. All grade 4 TEAEs resolved after day 36.
At day 28, 1 (2%) participant in the LZM008 group and 3 (6%) in the reference product group had positive anti-drug antibody (ADA) results. Also, 1 subject in the reference product group was positive for neutralizing antibodies. However, the authors noted there were no AEs attributable to these ADA findings, and the PK profiles of patients with ADAs were similar to those of ADA-negative subjects.
Reference
Cao G, Wang J, He J, et al. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects. Front Pharmacol. 2023;14:1111893. doi:10.3389/fphar.2023.1111893
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.